Clinical Trials Directory

Trials / Unknown

UnknownNCT06218498

Comparison of an Non-ablative Fractional 1565nm vs. an Ablative 2940-nm Fractional Er Laser for the Treatment of Androgenetic Alopecia

Comparison of an Non-ablative Fractional 1565nm vs. an Ablative 2940-nm Fractional Erbium-glass Laser for the Treatment of Male Androgenetic Alopecia

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
135 (estimated)
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
Sex
Male
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Laser sources have established their potential effect in inducing hair regrowth. No study has compared the effect of ablative fractional 2940-nm erbium yttrium aluminum garnet (Er: YAG) laser and non-fractional 15650nm fractional laser in the treatment of androgenetic alopecia (AGA).

Detailed description

The investigators performed a prospective study between to compare the efficacy and safety of ablative fractional 2940-nm erbium yttrium aluminum garnet (Er: YAG) laser and non-fractional 15650nm fractional laser in the treatment of androgenetic alopecia (AGA). The efficacy of the two therapies was evaluated by the investigator's Global Assessment (IGA) scores and the patient's Likert satisfaction scale at week 12 and week 24. Changes in total, terminal and villous hair count, total and terminal hair diameter, and AGA grade were also recorded. Adverse events were evaluated at each follow-up.

Conditions

Interventions

TypeNameDescription
DEVICEablative fractional 2940-nm Er: YAG laserAblative fractional 2940-nm Er: YAG laser (Dermablate MCL31, Asclepion Laser Technologies, Germany), the following parameters were used: model of N25%, energy density of 20-30J/cm2, pulse time of 300μs and one to two passes.
DEVICEnon-ablative fractional 1565nmNon-ablative fractional 1565nm (Lumenis, M22): Resur Fx len, energy of 30-35J/cm2, density of 200spot/cm2, overlap ≤10%.
DRUG5% Minoxidiltopical 5% minoxidil, 1 ml, twice daily

Timeline

Start date
2023-11-24
Primary completion
2024-06-30
Completion
2024-12-31
First posted
2024-01-23
Last updated
2024-01-23

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06218498. Inclusion in this directory is not an endorsement.